176 related articles for article (PubMed ID: 29947576)
1. A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.
Yuan G; Liu Q; Tong D; Liu G; Yi Y; Zhang J; Zhang Y; Wang LA; Wang L; Chen R; Guan Y; Yi X; Lan W; Jiang J
Cancer Biol Ther; 2018; 19(9):766-772. PubMed ID: 29947576
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
3. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
4. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
[TBL] [Abstract][Full Text] [Related]
5. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
[TBL] [Abstract][Full Text] [Related]
6. Novel and recurrent germline mutations in the VHL gene in 5 Arab patients with Von Hippel-Lindau disease.
Faiyaz-Ul-Haque M; Jamil M; Aslam M; Abalkhail H; Al-Dayel F; Basit S; Nawaz Z; Zaidi SHE
Cancer Genet; 2020 May; 243():1-6. PubMed ID: 32179488
[TBL] [Abstract][Full Text] [Related]
7. Metastases to hemangioblastomas in von Hippel-Lindau disease.
Jarrell ST; Vortmeyer AO; Linehan WM; Oldfield EH; Lonser RR
J Neurosurg; 2006 Aug; 105(2):256-63. PubMed ID: 17219831
[TBL] [Abstract][Full Text] [Related]
8. Von Hippel-Lindau syndrome. A pleomorphic condition.
Friedrich CA
Cancer; 1999 Dec; 86(11 Suppl):2478-82. PubMed ID: 10630173
[TBL] [Abstract][Full Text] [Related]
9. Von Hippel-Lindau disease.
Chittiboina P; Lonser RR
Handb Clin Neurol; 2015; 132():139-56. PubMed ID: 26564077
[TBL] [Abstract][Full Text] [Related]
10. Von Hippel-Lindau disease: strategies in early detection (renal-, adrenal-, pancreatic masses).
Hes FJ; Feldberg MA
Eur Radiol; 1999; 9(4):598-610. PubMed ID: 10354869
[TBL] [Abstract][Full Text] [Related]
11. Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
Taylor DG; Ilyas A; Mehta GU; Chen CJ; Schiff D; Oldfield EH; Asthagiri AR
J Clin Neurosci; 2018 Apr; 50():154-156. PubMed ID: 29396065
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
Tsimafeyeu I
J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
[TBL] [Abstract][Full Text] [Related]
13. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
Jonasch E; Donskov F; Iliopoulos O; Rathmell WK; Narayan VK; Maughan BL; Oudard S; Else T; Maranchie JK; Welsh SJ; Thamake S; Park EK; Perini RF; Linehan WM; Srinivasan R;
N Engl J Med; 2021 Nov; 385(22):2036-2046. PubMed ID: 34818478
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis as a tool in the differential diagnosis of VHL disease-related tumors.
Gijtenbeek J; Jacobs B; Boots-Sprenger S; Bonne A; Lenders J; Küsters B; Wesseling P; Jeuken J
Diagn Mol Pathol; 2005 Jun; 14(2):115-20. PubMed ID: 15905696
[TBL] [Abstract][Full Text] [Related]
15. [Does hemangioblastoma exist outside von Hippel-Lindau disease?].
Richard S; Beigelman C; Gerber S; Van Effenterre R; Gaudric A; Sahel M; Binaghi M; De Kersaint-Gilly A; Houtteville JP; Brunon JP
Neurochirurgie; 1994; 40(3):145-54. PubMed ID: 7723921
[TBL] [Abstract][Full Text] [Related]
16. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Hasanov E; Jonasch E
Expert Opin Investig Drugs; 2021 May; 30(5):495-504. PubMed ID: 33945366
[TBL] [Abstract][Full Text] [Related]
17. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment.
Shuin T; Yamasaki I; Tamura K; Okuda H; Furihata M; Ashida S
Jpn J Clin Oncol; 2006 Jun; 36(6):337-43. PubMed ID: 16818478
[TBL] [Abstract][Full Text] [Related]
18. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
[TBL] [Abstract][Full Text] [Related]
19. Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma.
Whaley JM; Naglich J; Gelbert L; Hsia YE; Lamiell JM; Green JS; Collins D; Neumann HP; Laidlaw J; Li FP
Am J Hum Genet; 1994 Dec; 55(6):1092-102. PubMed ID: 7977367
[TBL] [Abstract][Full Text] [Related]
20. Von Hippel-Lindau Disease With Multi-Organ Involvement: A Case Report and 8-Year Clinical Course With Follow-Up.
Yaghobi Joybari A; Azadeh P
Am J Case Rep; 2017 Nov; 18():1220-1224. PubMed ID: 29146893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]